Course : MOC Part II: Clinical Genetics and Genomics Literature Review (Issue 2017)
The Literature Review modules are comprised of 5-8 current and relevant literature articles in this specialty. The topics encompass new clinical applications or methodologies, diagnostic methods and approaches, management and treatment of genetic conditions, and relevant practice guidelines.
Diplomates are required to complete one Part II literature review module per 3 year timeframe of their ABMGG Continuing Certification MOC program.
New modules will be posted every two years. Each module will be available for a three-year period of time, so that up to two modules will be available at any given time.
Each literature review module consists of:
- Optional pre-reading test - Diplomates can take a 25 question pre-test. The score of the pre-test is revealed to the test taker only and a passing score does not exempt the diplomate from taking the post-test.
- Set of required reading -Full citations for five to eight specialty-specific articles will be listed.
- Post-reading test - Consists of the same 25 multiple-choice questions as the pre-test. Responses are scored immediately. Diplomates who do not achieve a passing score of 80% may repeat the test until a passing score is attained.
Date of Release: August 28th, 2017
Expiration Date: December 31, 2020
Estimate Time of Completion: 8 hours
Course must be completed by the expiration dates
Registration and Fees
CME Credits and MOC Part II Certificate ($25)
MOC Part II Certificate Only ABMGG Diplomates ($0/no cost)
At the conclusion of this course, participants should be able to:
1. Elaborate on the clinical importance the penetrance estimate for clinical manifestations of hereditary hemochromatosis (HH).
2. Describe the diagnosis, evaluation, and management of mitochondrial disorders.
3. Elaborate on the utility of whole exome sequencing in the identification of rare genetic disorders.
4. Describe the mechanism of CRISPR-Cas9 and its application to gene editing for gene therapy.
5. Describe the association between predisposing germline mutations in pediatric and adolescent cancer patients.